Icosagen builds manufacturing-ready CHO cell line for EPOK's EPRA-0322

Icosagen and EPOK Therapeutics said Monday they completed development of a stable CHO cell line for EPRA-0322, EPOK's lead antibody-like protein for anemia linked to chronic kidney disease. The work is meant to support IND submission and future GMP manufacturing of the complex tetravalent therapeutic.

Why it matters: - The project creates a manufacturing path for EPRA-0322, a complex therapeutic candidate aimed at anemia related to chronic kidney disease. - The cell line and process are designed to support IND submission, first-in-human trials and eventual commercial-scale production. - Icosagen says the platform can reduce development risk for non-platform protein modalities by pairing expression, analytics and manufacturing science early.

What happened: - Icosagen and EPOK Therapeutics announced the successful completion of a development project for EPOK's novel antibody EPRA-0322. - EPOK selected Icosagen's IcoCell® CHO cell line development platform to build a clinical and commercial manufacturing platform for the lead candidate. - EPRA-0322 is a mono-specific erythropoietin receptor agonist with a tetravalent Diabody-Fc-Fab architecture. - EPOK said the stable IcoCell® CHO cell line and process have helped advance EPRA-0322 toward IND submission.

The details: - Icosagen described the clone as highly productive, with upstream process work rapidly increasing the original titer. - EPOK said strong productivity, desired product quality attributes and process robustness were critical for scale-up and GMP manufacturing. - Icosagen said its integrated CRDMO approach combines expression, developability assessment, analytics and manufacturing sciences early in development. - The company said that approach has produced CHO producer cell lines with titers of up to 10 g/L in classical fed-batch bioreactors. - Icosagen said it studies each molecule's characteristics and builds a development and manufacturing path that preserves those properties through clinical development. - EPOK Therapeutics is a clinical-stage biopharmaceutical company focused on innovative therapeutic proteins for metabolic diseases. - Icosagen is an independent, family-owned European CRDMO founded 27 years ago. - Icosagen's platform spans antibody discovery, protein engineering, developability assessment, stable CHO cell line development, analytical characterization, process development and clinical GMP manufacturing. - Icosagen and EPOK provided contact details for partnering and business inquiries. - More information is available on EPOK Therapeutics and Icosagen.

Between the lines: - The announcement signals demand for specialized development support for complex biologics that do not fit standard manufacturing templates. - Icosagen is positioning its platform as a way to keep product quality and manufacturability aligned from the start, not as separate downstream tasks. - EPOK's decision suggests the company is prioritizing a path that can move a difficult molecule into clinical testing with fewer scale-up surprises.

What's next: - EPOK expects the work to support IND submission and preparation for first-in-human clinical trials. - Icosagen and EPOK indicated they may continue working together in the future. - The next commercial milestone will be GMP manufacturing readiness for later-stage development if EPRA-0322 advances.